Welcome to our dedicated page for Wuxi Apptec news (Ticker: WUXAY), a resource for investors and traders seeking the latest updates and insights on Wuxi Apptec stock.
WuXi AppTec Co., Ltd. (WUXAY) news covers developments at a global pharmaceutical and life sciences technology platform company that provides integrated CRDMO (Contract Research, Development and Manufacturing Organization) services. Company announcements highlight how WuXi AppTec supports drug discovery, development and manufacturing for thousands of customers across Asia, Europe and North America.
On this page, readers can follow news about WuXi AppTec’s segment performance in WuXi Chemistry, WuXi Testing and WuXi Biology, along with updates on its small molecule and TIDES (oligonucleotide and peptide) pipelines, backlog growth and capacity expansion. The company frequently reports revenue and profit trends for continuing operations, adjusted non-IFRS metrics, and backlog figures prepared under IFRSs and China Accounting Standards.
WuXi AppTec’s news flow also features regulatory and quality milestones, such as FDA inspections at its Changzhou and Taixing API manufacturing sites completed with no observations, as well as recognition for its facilities like the Nantong site’s Architizer A+Award. ESG-related announcements are another recurring theme, including inclusion in the FTSE4Good Index Series, MSCI ESG ratings, DJSI membership and validation of emissions reduction targets by the Science Based Targets initiative (SBTi).
Investors and observers can also track capital allocation actions such as cash dividends, interim and special dividends, A-share repurchase and cancellation programs, and H-share acquisition activities under share award and trust schemes. Bookmark this page to monitor WuXi AppTec’s official press releases, financial updates, ESG milestones and operational achievements that shape the outlook for the underlying business represented by WUXAY.
WuXi AppTec has successfully completed its acquisition of OXGENE, a UK-based contract research organization specializing in gene therapy technologies. This acquisition enhances WuXi AppTec's capabilities in offering comprehensive support for cell and gene therapy development. OXGENE will operate as a wholly-owned subsidiary under WuXi Advanced Therapies and will be WuXi ATU's first facility in Europe, allowing for accelerated service offerings and reduced costs in viral vector manufacturing. The strategic move aims to improve accessibility and effectiveness of advanced therapies globally.